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A COST-BENEFIT ANALYSIS OF AN 
INPATIENT, PHARMACY-MANAGED
MEDICATION ASSISTANCE PROGRAM FOR
INDIGENT PATIENTS:A 3-MONTH PILOT 
STUDY
Coleman CI1, Reddy P1, Quercia RA2, Gousse G2
1University of Connecticut, Storrs, CT, USA; 2Hartford
Hospital, Hartford, CT, USA
OBJECTIVES: Pharmacy-managed medication assistance
programs coordinate the supply of free drugs from phar-
maceutical manufacturers to indigent patients. These pro-
grams have the potential to recoup losses incurred by the
pharmacy department but whether this offsets the per-
sonnel cost of the program has not been well established.
The purpose of this study was to conduct a cost-beneﬁt
analysis of a pharmacy-managed medication assistance
program for indigent inpatients.
METHODS: Patients were enrolled into a pharmacy-
managed medication assistance program at Hartford
Hospital by healthcare professional referral or identiﬁca-
tion through uninsured patient administrative reports.
Patients were assisted in identifying pharmaceutical man-
ufacturers’ providing free drug and completing applica-
tions. The beneﬁt was deﬁned as value of drugs procured
using hospital cost. Costs to the pharmacy consisted of
personnel cost (time administering program x wage rate
$14.52/hour + 25% employee beneﬁts). Net beneﬁt was
calculated as the value of drug procured minus personnel
costs. A threshold sensitivity analysis was performed by
varying the value of the drugs procured, personnel time
and wage rate.
RESULTS: From October through December 2001, 20
patients were enrolled into the program with 49 applica-
tions ﬁled (approval rate = 92%). Cardiovascular and
oncology/hematology comprised 63% and 18% of the
drugs provided in the program with a beneﬁt of $4,686
and $12,966, respectively. The total beneﬁt for all drugs
was $18,730. An average of 2.25 hours/day was spent
administering the program, resulting in personnel costs 
of $2,205. The net beneﬁt of the program was $16,525.
Upon sensitivity analysis, the breakeven point was
reached when drug value was reduced to $2,205, per-
sonnel time increased to 1,032 hours, and the wage rate
increased to $116/hour.
CONCLUSION: This pilot study illustrates that a phar-
macy-managed, medication assistance program for 
indigent inpatients was cost-beneﬁcial. Based on these
ﬁndings the inpatient program will be continued. An 
outpatient program will be initiated and subsequently
evaluated.
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CHILDREN IN NEED OF PHARMACARE:
ANALYSIS OF MEDICATION FUNDING
REQUESTS AT THE TORONTO HOSPITAL FOR
SICK CHILDREN
Ungar WJ1, Daniels C2, McNeill T2, Seyed M1
1The Hospital for Sick Children Research Institute,Toronto,
ON, Canada; 2The Hospital for Sick Children,Toronto, ON,
Canada
OBJECTIVES: The Hospital for Sick Children (HSC)
Patient Amenities Fund (PAF) covers out-of-pocket medi-
cation expenses for needy families that are not provided
by private or government health plans. Recently, a sig-
niﬁcant increase in PAF expenditures for medications 
has been observed. The study objective was to examine
PAF medication expenditure trends, the reasons for fund
requests and the demographics of requesting families to
reveal limitations of existing pharmaceutical policies in
Ontario.
METHODS: The study was a retrospective descriptive
analysis of medication requests in 1998–99. Family
demographics and socio-economic status, medications
and amount requested, reasons for request, duration of
beneﬁt, type of drug plans available and government 
plan process issues were extracted from PAF request
forms, social work reports, discharge planning reports
and patient charts. Descriptive statistics were used to
analyse categorical and continuous variables. Percent
change over time in the number and dollar amount of
requests was determined.
RESULTS: Eighty-six applicants submitted 112 requests
over the two-year period. Most requests were for children
with cancer, neurological disorders and children under-
going organ transplants. The number of medication
requests increased by 67% from 1998 to 1999. Medica-
tion expenditures were $22,404 in 1999, a 39% increase
over 1998. The majority of requests (83%) came from
two-parent nuclear families. The father, mother, or both
were employed in 70% of the requests. Eighty-nine
percent of requests came from families with no private
drug plan. High deductibles, waiting time, application
form complexity and request denials were cited as prob-
lems encountered with government drug plans.
CONCLUSIONS: Whereas Ontario drug plan programs
may meet the needs of seniors and families receiving
social assistance, the need for funds to pay for medica-
tions for children persists. The current patchwork of 
government drug plans and community agencies may 
not be effective in ensuring easy and timely access to 
necessary medications.
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OBJECTIVE: This research contributes to the inﬂuence
of cost on clinical decision-making. It analyses the impact
of cost to the patient rather than knowledge of drug
prices/costs on physicians’ decisions. It is based on 
ﬁndings from a physicians’ cost sensitiveness analysis
from the BIOMED/ENDEP project called patient 
charges and decision making behaviors of consumers and
physicians.
METHODS: A “reversed” conjoint value analysis (CVA)
is run on four patient attributes rather than product
attributes. The four attributes are patient affordability,
patient demand for cheaper drugs, severity of disease and
risk factors and patient expenses on other diseases. The
design allows a large number of levels for analyzing
potential shifts with complex cost-sharing arrangements.
Randomization of cases is ensured through a stepwise
procedure and 39 clinical cases out of 54 are discarded.
High levels of orthogonality are achieved (over 90% of
D efﬁciency) and only main effects are calculated. The
questionnaire is administered on four randomized
samples of 100 physicians in France, the UK, Finland and
Italy. The statistical analysis is run with a linear regres-
sion better suited for a rate-scale dependent variable.
RESULTS: Average physician’s utilities and an outcome
measure of drug prescribing are presented. Patient
demand for cheaper drugs and patient expenses on other
diseases are the most important attributes to inﬂuence
physicians’cost sensitivity. Cost sensitive physicians shift
from top selling drugs to cheaper drugs under patient
needs. Some links with drug appropriateness issues are
also highlighted.
CONCLUSIONS: The analysis is useful for policy makers
interested in prescription drug policy, especially in the
USA, where direct health care outspendings increase at 
a fast rate. It provides evidence for educational policies
and behavioral changes towards physicians and patients,
and a potential decision tool to drug beneﬁt managers in
order to predict prescribing cost in response to different
cost-sharing policies.
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HEALTH-RELATED QUALITY OF LIFE IN
HEMOPHILIA AND VON WILLEBRAND’S
DISEASE: MEASUREMENT PROPERTIES OF THE
HEALTH UTILITIES INDEX
Horsman JR, Furlong W, Barr RD, Sek J, Pai M,Walker I
McMaster University, Hamilton, ON, Canada
OBJECTIVES: To test the hypotheses that increasing
severity of factor VIII/IX deﬁciency in hemophiliacs 
and severity in von Willebrand’s Disease (VWD) patients
would be associated with lower health-related quality of
life (HRQL), and that hepatitis and HIV positivity would
further impair HRQL.
METHODS: A cross-sectional mail survey of a popula-
tion-based cohort from a regional hemophilia program 
in Ontario Canada was conducted of mild, moderate and
severe hemophiliacs and T1, T2 and T3 VWD patients
over 13 years of age. Patients reported their health status
“during the past 4 weeks” using a standard Health 
Utilities Index (HUI) 15-item questionnaire. Responses
were mapped to the generic HUI Mark 3 (HUI3) health-
status classiﬁcation system. Eight single-attribute mor-
bidity scores and one HRQL score were determined using
published utility functions.
RESULTS: The response rate was > 85% (101 of 115
hemophiliacs, 28 of 36 VWD patients). Morbidity was
greater in hemophiliacs and VWD than in the general
population (p < 0.001). For hemophiliacs the burden cor-
related with the category of disease, mild < moderate <
severe (p < 0.05). Hepatitis and HIV positivity imposed
additional burdens, mainly in ambulation and pain (p <
0.005). VWD female patients reported important burdens
in emotion, cognition and pain with a mean HRQL score
lower than for severe hemophiliacs (0.55 vs. 0.65). The
differences in mean HUI3 scores between males and
females were large (> 0.14) for HRQL (p < 0.05) as well
as for emotion (p < 0.05), cognition (p = 0.01) and pain
(p = 0.01).
CONCLUSIONS: Despite improvements in the effective-
ness and utilization of clotting factor concentrates, hemo-
philiacs continue to suffer a serious burden of morbidity
providing a basis for future economic evaluation of 
the costs and consequences of health care interventions.
The heavy burden of morbidity reported by females with
VWD provides direction for support and therapeutic
intervention given little consideration to date. Evidence
supports the construct validity of the HUI3.
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